European Urology

Review

Molecular Biology of the Androgen Receptor: From Molecular Understanding to the Clinic

Eder I.E. · Culig Z. · Putz T. · Nessler-Menardi C. · Bartsch G. · Klocker H.

Author affiliations

Department of Urology, University of Innsbruck, Austria

Keywords: Androgen receptorAndrogen insensitivityMutationsProstate cancerTherapy

Related Articles for ""
Eur Urol 2001;40:241–251
https://doi.org/10.1159/000049782

Log in to MyKarger to check if you already have access to this content.




Forgot your password
Sign up to MyKarger

Buy

  • FullText & PDF
  • Unlimited re-access via MyKarger
  • Unrestricted printing, no saving restrictions for personal use
read more
CHF 38.00 *
EUR 35.00 *
USD 39.00 *

Select

KAB

Buy a Karger Article Bundle (KAB) and profit from a discount!


If you would like to redeem your KAB credit, please log in.

Save over 20% compared to the individual article price.

Learn more

Rent/Cloud

  • Rent for 48h to view
  • Buy Cloud Access for unlimited viewing via different devices
  • Synchronizing in the ReadCube Cloud
  • Printing and saving restrictions apply
Rental: USD 8.50
Cloud: USD 20.00

Select

Subscribe

For eJournal Archive and eJournal Backfiles information please contact Karger service

* The final prices may differ from the prices shown due to specifics of VAT rules.

Article / Publication Details

First-Page Preview
Abstract of Review

Published online: October 29, 2001
Issue release date: September 2001

Number of Print Pages: 11
Number of Figures: 3
Number of Tables: 1

ISSN: 0302-2838 (Print)
eISSN: 1873-7560 (Online)

For additional information: https://www.karger.com/EUR

Abstract

The androgen receptor (AR) is the key regulatory element of androgen signaling in the cell. It mediates action of androgens and is therefore essential for growth, function and differentiation of the human male urogenital tract. Genetic alterations in the AR gene may cause impaired development resulting in androgen insensitivity syndromes (AIS) or in neurodegenerative diseases like Kennedy syndrome. Besides the crucial role in the process of virilization during embryogenesis and puberty, the AR also plays an important role in the adult man as the intracellular mediator of androgen action. Androgen withdrawal and/or AR blockade is the main choice of treatment of nonorgan–confined prostate cancer. Unfortunately, this treatment is only palliative and a majority of these tumors recur and progress to an androgen–independent and therapy–resistant stage. Recent findings gave new insight into the molecular structure and function of the AR and improved our understanding about prostate cancer progression, consequently resulting in the development of novel treatments. It has become evident that the AR is a nuclear transcription factor that can be activated ligand–dependently by androgens as well as ligand–independently by other hormones and various growth factors, respectively. Moreover, it was shown that the interaction of the AR with other proteins of the intracellular signal transduction cascade may promote prostate tumor growth. This review will summarize the most important findings about the AR and the androgen signaling pathway to improve the understanding of prostate diseases and novel treatment strategies that may be useful in the clinic.



Related Articles:

References

  1. Wilding G: Endocrine control of prostate cancer. Cancer Surv 1995;23:43–62.
    External Resources
  2. Wilson JD, George FW, Renfree MB: The endocrine role in mammalian sexual differentiation. Recent Prog Horm Res 1995;50:349–364.
    External Resources
  3. Wilson JD: Role of dihydrotestosterone in androgen action. Prostate Suppl 1996;6:88–92.
    External Resources
  4. Grino PB, Griffin JE, Wilson JD: Testosterone at high concentrations interacts with the human androgen receptor similarly to dihydrotestosterone. Endocrinology 1990;126: 1165–1172.
    External Resources
  5. Giguere V: Orphan nuclear receptors: From gene to function. Endocr Rev 1999;20:689– 725.
  6. Whitfield GK, Jurutka PW, Haussler CA, Haussler MR: Steroid hormone receptors: Evolution, ligands, and molecular basis of biologic function. J Cell Biochem 1999(suppl 32–33):110–122.
  7. Kato S: The function of vitamin D receptor in vitamin D action. J Biochem (Tokyo) 2000; 127:717–722.
    External Resources
  8. Peterson CM: Estrogen and progesterone receptors: An overview from the year 2000. J Soc Gynecol Investig 2000;7(suppl):S3–S7.
  9. Reichardt HM, Tronche F, Berger S, Kellendonk C, Schutz G: New insights into glucocorticoid and mineralocorticoid signaling: Lessons from gene targeting. Adv Pharmacol 2000;47:1–21.
    External Resources
  10. Chang CS, Kokontis J, Liao ST: Structural analysis of complementary DNA and amino acid sequences of human and rat androgen receptors. Proc Natl Acad Sci USA 1988;85: 7211–7215.
  11. Lubahn DB, Joseph DR, Sar M, Tan J, Higgs HN, Larson RE, French FS, Wilson EM: The human androgen receptor: Complementary deoxyribonucleic acid cloning, sequence analysis and gene expression in prostate. Mol Endocrinol 1988;2:1265–1275.
    External Resources
  12. Trapman J, Klaassen P, Kiuper GGJM, van der Korput JAGM, Faber PW, van Rooij HCJ, Geurts van Kessel A, Voorhorst MM, Mulder E, Brinkmann AO: Cloning, structure and expression of a cDNA encoding the human androgen receptor. Biochem Biophys Res Commun 1988;153:241–248.
    External Resources
  13. Tilley WD, Marcelli M, Wilson JD, McPhaul MJ: Characterization and expression of a cDNA encoding the human androgen receptor. Proc Natl Acad Sci USA 1989;86:327–331.
    External Resources
  14. Smith DF: Dynamics of heat–shock protein 90–progesterone receptor binding and the disactivation loop model for steroid receptor complexes. Mol Endocrinol 1993;7:1418–1429.
    External Resources
  15. Veltschote J, Berrevoets CA, Zegers ND, van der Kvast TH, Grootegoed JA, Mulder E: Hormone–induced dissociation of the androgen receptor–heat–shock protein complex. Use of a new monoclonal antibody to distinguish transformed from nontransformed receptors. Biochemistry 1992;31:7422–7430.
    External Resources
  16. Truss M, Beato M: Steroid hormone receptors: Interaction with deoxyribonucleic acid and transcription factors. Endocr Rev 1993;14: 459–479.
    External Resources
  17. Tsai MJ, O’Malley BW: Molecular mechanisms of action of steroid/thyroid receptor superfamily members. Annu Rev Biochem 1994; 63:451–486.
    External Resources
  18. Page MJ, Parker MG: Effect of androgen on the transcription of rat prostatic binding protein genes. Mol Cell Endocrinol 1982;28:343– 355.
  19. Riegman PH, Vlietstra RJ, van der Korput HA, Romijn JC, Trapman J: Identification and androgen–regulated expression of two major human glandular kallikrein–1 (hGK–1) mRNA species. Mol Cell Endocrinol 1991;76:181– 190.
  20. Riegman PH, Vlietstra RJ, van der Korput JA, Brinkmann AO, Trapman J: The promoter of the prostate–specific antigen gene contains a functional androgen responsive element. Mol Endocrinol 1991;9:1921–1930.
  21. Adler AJ, Danielsen M, Robins DM: Androgen–specific gene activation via a consensus glucocorticoid response element is determined by interaction with nonreceptor factors. Proc Natl Acad Sci USA 1992;89:11660–11663.
    External Resources
  22. Murtha P, Tindall DJ, Young C: Androgen induction of a human prostate–specific kallikrein hKLK2: Characterization of an androgen response element in the 5’ promoter region of the gene. Biochemistry 1993;32:6459–6464.
    External Resources
  23. Rennie PS, Bruchovsky N, Leco KJ, Sheppard PC, McQueen SA, Cheng H, Snoek R, Hamel A, Bock ME, MacDonald BS, Nickel BE, Chang C, Liao S, Cattini PA, Matusik RJ: Characterization of two cis–acting DNA elements involved in the androgen regulation of the probasin gene. Mol Endocrinol 1993;7:23– 36.
  24. Blackwell KL, Bostwick DG, Myers RP, Zincke H, Oesterling JE: Combining prostate–specific antigen with cancer and gland volume to predict more reliably pathologic stage: The influence of prostate–specific antigen cancer density. J Urol 1994;151:1565–1570.
    External Resources
  25. Perry JE, Tindall DJ: Androgens regulate the expression of proliferating cell nuclear antigen posttranscriptionally in the human prostate cancer cell line LNCaP. Cancer Res 1996;56: 1539–1544.
    External Resources
  26. Sartorius CA, Melville MY, Hovland AR, Tung L, Takimoto GS, Horwitz KB: A third transactivation function (AF3) of human progesterone receptors located in the unique N–terminal segment of the B–isoform. Mol Endocrinol 1994;8:1347–1360.
    External Resources
  27. Jenster G, van der Korput HAGM, van Vroonhoven C, van der Kwast TH, Trapman J, Brinkmann AO: Domains of the human androgen receptor involved in steroid binding, transcriptional activation, and subcellular localization. Mol Endocrinol 1991;5:1396–1404.
    External Resources
  28. Jenster K, van der Korput HAGM, Trapman J, Brinkmann AO: Identification of two transcription activation units in the N–terminal domain of the human androgen receptor. J Biol Chem 1995;270:7341–7346.
    External Resources
  29. Moilanen A, Rouleau N, Ikonen T, Palvimo JJ, Jänne OA: The presence of a transcription activation function in the hormone–binding domain of androgen receptor is revealed by studies in yeast cells. FEBS Lett 1997;412:355– 358.
  30. Berrevoets CA, Doesburg P, Steketee K, Trapman J, Brinkmann AO: Functional interactions of the AF–2 activation domain core region of the human androgen receptor with the amino–terminal domain and with the transcriptional coactivator TIF2 (transcriptional intermediary factor 2). Mol Endocrinol 1998;12:1172–1183.
    External Resources
  31. Zhou ZX, Kemppainen JA, Wilson EM: Identification of three proline–directed phosphorylation sites in the human androgen receptor. Mol Endocrinol 1995;9:605–615.
    External Resources
  32. Blok LJ, de Ruiter PE, Brinkmann AO: Androgen receptor phosphorylation. Endocr Res 1996;22:197–219.
    External Resources
  33. Blok LJ, de Ruiter PE, Brinkmann AO: Forskolin–induced dephosphorylation of the androgen receptor impairs ligand binding. Biochemistry 1998;37:3850–3857.
    External Resources
  34. Weigel NL, Zhang Y: Ligand–independent activation of steroid hormone receptors. J Mol Med 1998;76:469–479.
    External Resources
  35. Chakravarti D, LaMorte VJ, Nelson MC, Nakajima T, Schulman IG, Juguilon H, Montminy M, Evans RM: Role of CBP/P300 in nuclear receptor signalling. Nature 1996;383: 99–103.
    External Resources
  36. Gottlieb B, Beitel LK, Lumbroso R, Pinsky L, Triforo M: Update of the androgen receptor gene mutations database. Hum Mutat 1999;14: 103–114.
    External Resources
  37. Torchia J, Glass C, Rosenfeld MG: Co–activators and co–repressors in the integration of transcriptional responses. Curr Opin Cell Biol 1998;10:373–383.
    External Resources
  38. Alen P, Claessens F, Schoenmakers E, Swinnwn JV, Verhoeven G, Rombauts W, Peeters B: Interaction of the putative androgen receptor–specific coactivator ARA70/ELE1α with multiple steroid receptors and identification of an internally deleted ELE1β isoform. Mol Endocrinol 1999;13:117–128.
    External Resources
  39. Kang HY, Yeh S, Fujimoto N, Chang C: Cloning and characterization of human prostate coactivator ARA54, a novel protein that associates with the androgen receptor. J Biol Chem 1999;274:8570–8576.
    External Resources
  40. Nessler–Menardi C, Jotova I, Culig Z, Eder IE, Putz T, Bartsch G, Klocker H: Expression of androgen receptor coregulatory proteins in prostate cancer and stromal cell culture models. Prostate 2000;45:124–131.
    External Resources
  41. Miyamoto H, Yeh S, Wilding G, Chang C: Promotion of agonist activity of antiandrogens by the androgen receptor coactivator, ARA70, in human cancer DU145 cells. Proc Natl Acad Sci USA 1998;95:7379–7384.
    External Resources
  42. Schneikert J, Peterziel H, Defossez PA, Klocker H, Launoit Y, Cato AC: Androgen receptor–Ets protein interaction is a novel mechanism for steroid hormone–mediated down–modulation of matrix metalloproteinase expression. J Biol Chem 1996;271:23907–23913.
    External Resources
  43. Sato N, Sadar MD, Bruchovsky N, Saatcioglu F, Rennie PS, Sato S, Lange PH, Gleave ME: Androgenic induction of prostate–specific antigen gene is repressed by protein–protein interaction between the androgen receptor and AP–1/c–Jun in the human prostate cancer cell line LNCaP. J Biol Chem 1997;272:17485–17494.
    External Resources
  44. Radmayr C, Culig Z, Hobisch A, Corvin S, Bartsch G, Klocker H: Analysis of a mutant androgen receptor offers a treatment modality in a patient with partial androgen insensitivity syndrome. Eur Urol 1998;33:222–226.
    External Resources
  45. McPhaul MJ, Griffin JE: Male pseudohermaphroditism caused by mutations of the human androgen receptor. J Clin Endocrinol Metab 1999;84:3435–3441.
    External Resources
  46. Ahmed SF, Cheng A, Dovey L, Hawkins JR, Martin H, Rowland J, Shimura N, Tait AD, Hughes IA: Phenotypic features, androgen receptor binding, and mutational analysis in 278 clinical cases reported as androgen insensitivity syndrome. J Clin Endocrinol Metab 2000; 85:658–665.
    External Resources
  47. Lubahn DB, Joseph DR, Sullivan PM, Willard HF, French FS, Wilson EM: Cloning of human androgen receptor complementary DNA and localization to the X–chromosome. Science 1988;240:327–330.
    External Resources
  48. Brinkmann AO, Jenster G, Kuiper GG, Ris–Stalpers C, Van Laar JH, Van der Korput JA, Degenhart HJ, Trifiro MA, Pinsky L, Romalo G, Schweikert HU: The human androgen receptor: Structure/function relationship in normal and pathological situations. J Steroid Biochem Mol Biol 1992;41:361–368.
    External Resources
  49. Kantoff P, Giovannucci E, Brown M: The androgen receptor CAG repeat polymorphism and its relationship to prostate cancer. Biochim Biophys Acta 1998;1378:C1–C5.
    External Resources
  50. La Spada AR, Wilson EM, Lubahn DB, Harding AE, Fischbeck KH: Androgen receptor gene mutations in X–linked spinal and bulbar muscular atrophy. Nature 1991;352:77–79.
    External Resources
  51. La Spada AR, Roling DB, Harding AE, Warner CL, Spiegel R, Hausmanowa–Petrusewicz I, Yee WC, Fischbeck KH: Meiotic stability and genotype phenotype correlation of the trinucleotide repeat in X–linked spinal and bulbar muscular atrophy. Nat Genet 1992;2:301–303.
    External Resources
  52. Neuschmid–Kaspar F, Gast A, Peterziel H, Schneikert J, Muigg A, Radmayr C, Klocker H, Bartsch G, Cato AC: CAG–repeat expansion in androgen receptor in Kennedy’s disease is not a loss of function mutation. Mol Cell Endocrinol 1996;117:149–156.
    External Resources
  53. Ellerby LM, Hackam AS, Propp SS, Ellerby HM, Rabizadej S, Cashman NR, Trifiro MA, Pinsky L, Wellington CL, Salvesen GS, Hayden MR, Bredesen DE: Kennedy’s disease: Caspase cleavage of the androgen receptor is a crucial event in cytotoxicity. J Neurochem 1999;72:185–195.
    External Resources
  54. Arbizu T, Santamaria J, Gomez JM, Quilez A, Serra JP: A family with adult spinal and bulbar muscular atrophy, X–linked inheritance and associated testicular failure. J Neurol Sci 1983; 59:371–382.
    External Resources
  55. Kobayashi Y, Miwa S, Merry DE, Kume A, Mei L, Doyu M, Sobue G: Caspase–3 cleaves the expanded androgen receptor protein of spinal and bulbar muscular atrophy in a polyglutamine repeat length–dependent manner. Biochem Biophys Res Commun 1998;252: 145–150.
    External Resources
  56. Kobayashi Y, Kume A, Li M, Doyu M, Hata M, Ohtsuka K, Sobue G: Chaperones Hsp70 and Hsp40 suppress aggregate formation and apoptosis in cultured neuronal cells expressing truncated androgen receptor protein with expanded polyglutamine tract. J Biol Chem 2000;275:8772–8778.
    External Resources
  57. McCampbell A, Taylor JP, Taye AA, Robitschek J, Li M, Walcott J, Merry D, Chai Y, Paulson H, Sobue G, Fischbeck KH: CREB–binding protein sequestration by expanded polyglutamine. Hum Mol Genet 2000;9:2197– 2202.
  58. Sculptoreanu A, Abramovici H, Abdullah AA, Bibikova A, Panet–Raymond V, Frankel D, Schipper HM, Pinsky L, Trifiro MA: Increased T–type Ca2+ channel activity as a determinant of cellular toxicity in neuronal cell lines expressing polyglutamine–expanded human androgen receptors. Mol Cell Biochem 2000; 203:23–31.
    External Resources
  59. Grierson AJ, Mootoosamy RC, Miller CC: Polyglutamine repeat length influences human androgen receptor/c–Jun–mediated transcription. Neurosci Lett 1999;277:9–12.
    External Resources
  60. Chamberlin NL, Driver ED, Miesfield RL: The length and location of CAG trinucleotide repeats in the androgen receptor N–terminal domain effect transactivation function. Nucleic Acids Res 1994;22:3181.
    External Resources
  61. Kazemi–Esfarjani P, Trifiro MA, Pinsky L: Evidence for a repressive function of the long polyglutamine tract in the human androgen receptor: Possible pathogenetic relevance for the CAG expanded neuronopathies. Hum Mol Genet 1995;4:523–527.
    External Resources
  62. Edwards A, Hammond HA, Jin L, Caskey CT, Chakraborty R: Genetic variation at five trimeric and tetrameric tandem repeat loci in four human population groups. Genomics 1992;12:241–253.
    External Resources
  63. Giovannucci E, Stampfer MJ, Krihivas K, Brown M, Brufsky A, Talcott J, Hennekens CH, Kantoff PW: The CAG repeat within the androgen receptor gene and its relationship to prostate cancer. Proc Natl Acad Sci USA 1997; 94:3320–3323.
    External Resources
  64. Ingles SA, Ross RK, Yu MC, Irvine RA, La Pera G, Haile RW, Coetzee GA: Association of prostate cancer risk with genetic polymorphisms in vitamin D receptor and androgen receptor. J Natl Cancer Inst 1997;89:166–170.
    External Resources
  65. Nam RK, Elhaji Y, Krahn MD, Hakimi J, Ho M, Chu W, Sweet J, Trachtenberg J, Jewett MAS, Narod SA: Significance of the CAG repeat polymorphism of the androgen receptor gene in prostate cancer progression. J Urol 2000;164:567–572.
    External Resources
  66. Irvine RA, Yu MC, Ross RK, Coetzee GA: The CAG and GGC microsatellites of the androgen receptor gene are in linkage disequilibrium in men with prostate cancer. Cancer Res 1995;55: 1937–1940.
  67. Sartor O, Zheng Q, Eastham JA: Androgen receptor gene CAG repeat length varies in a race–specific fashion in men without prostate cancer. Urology 1999;53:378–380.
    External Resources
  68. Hsing AW, Gao YT, Wu G, Wang X, Deng J, Chen YL, Sesterhenn IA, Mostofi FK, Benichou J, Chang C: Polymorphic CAG and GGN repeat lengths in the androgen receptor gene and prostate cancer risk: A population–based case–control study in China. Cancer Res 2000; 60:5111–5116.
    External Resources
  69. Bratt O, Borg A, Kristoffersson U, Lundgren R, Zhang QX, Olsson H: CAG repeat length in the androgen receptor gene is related to age at diagnosis of prostate cancer and response to endocrine therapy, but not to prostate cancer risk. Br J Cancer 1999;81:672–676.
    External Resources
  70. Jin B, Beilin J, Zajac J, Handelsman DJ: Androgen receptor gene polymorphism and prostate zonal volumes in Australian and Chinese men. J Androl 2000;21:91–98.
    External Resources
  71. Lange EM, Chen H, Brierley K, Livermore H, Wojno KJ, Langefeld CD, Lange K, Cooney KA: The polymorphic exon 1 androgen receptor CAG repeat in men with a potential inherited predisposition to prostate cancer. Cancer Epidemiol Biomarkers Prev 2000;9:439–442.
    External Resources
  72. Morton RA Jr: Racial differences in adenocarcinoma of the prostate in North American men. Urology 1994;44:637–645.
    External Resources
  73. Elo JP, Kvist L, Leinonen K, Isomaa V, Henttu P, Kukkarinen O, Vihko P: Mutated human androgen receptor gene detected in a prostatic cancer patient is also activated by estradiol. J Clin Endocrinol Metabol 1995;80:3494–3500.
    External Resources
  74. Taplin ME, Bubley GJ, Ko YJ, Small EJ, Upton M, Rajeshkumar B, Balk SP: Selection for androgen receptor mutations in prostate cancers treated with androgen antagonist. Cancer Res 1999;59:2511–2515.
    External Resources
  75. Suzuki H, Sato N, Watabe Y, Masai M, Seino S, Shimazaki J: Androgen receptor gene mutations in human prostate cancer. J Steroid Biochem Mol Biol 1993;46:759–765.
    External Resources
  76. Taplin ME, Bubley GJ, Shuster TD, Frantz ME, Spooner AE, Ogata GK, Keer HN, Balk SP: Mutation of the androgen–receptor gene in metastatic androgen–independent prostate cancer. N Engl J Med 1995;332:1393–1398.
    External Resources
  77. Marcelli M, Ittmann M, Mariani S, Sutherland R, Nigam R, Murthy L, Zhao Y, DiConcini D, Puxeddu E, Esen A, Eastham J, Weigel NL, Lamb DJ: Androgen receptor mutations in prostate cancer. Cancer Res 2000;60:944–949.
    External Resources
  78. Veldscholte J, Ris–Stalpers C, Kuiper GGJM, Jenster G, Berrevoets C, Claassen E, van Rooij HCJ, Trapman J, Brinkmann AO, Mulder E: A mutation in the ligand binding domain of the androgen receptor of human LNCaP cells affects steroid binding characteristics and response to anti–androgens. Biochem Biophys Res Commun 1990;17:534–540.
  79. Horoszewicz JS, Leong SS, Kawinski E, Karr JP, Rosenthal H, Chu TM, Mirand EA, Murphy EA: LNCaP model of human prostatic carcinoma. Cancer Res 1983;43:1809–1818.
    External Resources
  80. Gaddipati JP, McLeod DG, Heidenberg HB, Sesterhenn IA, Finger MJ, Moul JW, Srivastava S: Frequent detection of codon 877 mutation in the androgen receptor gene in advanced prostate cancers. Cancer Res 1994;54:2861– 2866.
  81. Kleinerman DI, Troncoso P, Pisters LL, Navone NM, Hsieh JT, Logothetis CJ, von Esch– enbach AC, Sleddens HFBM, van der Kwast TH, Brinkmann AO, Schröder FH, Trapman J: Expression and structure of the androgen receptor in bone metastases of hormone refractory prostate cancer. J Urol (Suppl) 1996;155: 624A.
  82. Suzuki H, Akakura K, Komiya A, Aida S, Akimoto S, Shimazaki J: Codon 877 mutation in the androgen receptor gene in advanced prostate cancer. Relation to antiandrogen withdrawal syndrome. Prostate 1996;29:153–158.
    External Resources
  83. Culig Z, Hobisch A, Cronauer MV, Cato ACB, Hittmair A, Radmayr C, Eberle J, Bartsch G, Klocker H: Mutant androgen receptor detected in an advanced–stage prostatic carcinoma is activated by adrenal androgens and progesterone. Mol Endocrinol 1993;7:1541–1550.
    External Resources
  84. Peterziel H, Culig Z, Stober J, Hobisch A, Radmayr C, Bartsch G, Klocker H, Cato AC: Mutant androgen receptors in prostatic tumors distinguish between amino–acid–sequence requirements for transactivation and ligand binding. Int J Cancer 1995;63:544–550.
    External Resources
  85. Bubley G, Fenton M, Fertig A, DeWolf W, Shuster T, Balk S: The hormonal sensitivity of androgen receptor (AR) mutations derived from human tumors. Cancer Res (Proceedings) 1996;37:246.
  86. Culig Z, Stober J, Gast A, Peterziel H, Hobisch A, Radmayr C, Hittmair A, Bartsch G, Cato A, Klocker H: Activation of two mutant androgen receptors from human prostatic carcinoma by adrenal androgens and metabolic derivatives of testosterone. Cancer Detect Prev 1996;20: 68–75.
    External Resources
  87. Zhao XY, Malloy PJ, Krishnan AV, Swami S, Navone NM, Peehl DM, Feldman D: Glucocorticoids can promote androgen–independent growth of prostate cancer cells through a mutated androgen receptor. Nat Med 2000;6:703– 706.
  88. Van Cauter E, Leproult R, Kupfer DJ: Effects of gender and age on the levels and circadian rhythmicity of plasma cortisol. J Clin Endocrinol Metab 1996;81:2468–2473.
    External Resources
  89. Nazareth LV, Stenoinen DL, Bingman WE, James AJ, Wu C, Zhang Y, Edwards DP, Mancini M, Marcelli M, Lamb DJ, Weigel NL: A C619Y mutation in the human androgen receptor causes inactivation and mislocalization of the receptor with concomitant sequestration of SRC–1. Mol Endocrinol 1999;13:2065– 2075.
  90. Rosenberg AG, von Eschenbach AC: Hormonal therapy for prostate cancer. Semin Surg Oncol 1990;6:71–76.
    External Resources
  91. Griffiths K, Morton MS, Nicholson RI: Androgens, androgen receptors, antiandrogens and the treatment of prostate cancer. Eur Urol 1997;32:24–40.
    External Resources
  92. Kyprianou N, English HF, Isaacs JT: Programmed cell death during regression of PC–82 human prostate cancer following androgen ablation. Cancer Res 1990;50:3748–3753.
    External Resources
  93. Leewansangtong S, Crawford ED: Maximal androgen withdrawal for prostate cancer therapy: Current status and future potential. Endocr Rel Cancer 1998;5:325–339.
  94. Kuil CW, Berrevoets CA, Mulder E: Ligand–induced conformational alterations of the androgen receptor analyzed by limited trypsiniza– tion: Studies on the mechanism of antiandrogen action. J Biol Chem 1995;270: 27569– 27576.
  95. Crawford ED, Eisenberger MA, McLeod DG, Spaulding JT, Benson R, Dorr FA, Blumenstein BA, Davis MA, Goodman PJA: A controlled trial of leuprolide with and without flutamide in prostatic carcinoma. N Engl J Med 1989;321:419–424.
    External Resources
  96. Labrie F, Belanger A, Simard J, Labrie C, Dupont A: Combination therapy for prostate cancer – Endocrine and biologic basis of its choice as new standard first–line therapy. Cancer 1993;71:1059–1067.
    External Resources
  97. Denis LJ, Keuppens F, Smith PH, Whelan P, de Moura JL, Newling D, Bono A, Sylvester R: Maximal androgen blockade: Final analysis of EORTC phase III trial 30853. EORTC Genito–Urinary Tract Cancer Cooperative Group and the EORTC Data Center. Eur Urol 1998;33:144–151.
    External Resources
  98. Van der Kwast TH, Schalken J, Ruizeveld de Winter JA, Van Vroonhoven CCJ, Mulder E, Boersma W, Trapman J: Androgen receptors in endocrine–therapy–resistant human prostate cancer. Int J Cancer 1991;48:189–193.
    External Resources
  99. Ruizevelt de Winter JA, Janssen PJA, Sleddens HMEB, Verleun–Mooijman MCT, Trapman J, Brinkmann AO, Santerse AB, Schröder FH, van der Kwast TH: Androgen receptor status in localized and locally progressive hormone refractory human prostate cancer. Am J Pathol 1994;144:735–746.
    External Resources
  100. Hobisch A, Culig A, Radmayr C, Bartsch G, Klocker H, Hittmair A: Distant metastases from prostatic carcinoma express androgen receptor protein. Cancer Res 1995;55:3068– 3072.
  101. Hobisch A, Culig Z, Radmayr C, Bartsch G, Klocker H, Hittmair A: Androgen receptor status of lymph node metastases from prostate cancer. Prostate 1996;28:129–135.
    External Resources
  102. Visakorpi T, Hyytinen E, Koivisto P, Tanner M, Keinänen R, Palmberg C, Palotie A, Tammela T, Isola J, Kallioniemi OP: In vivo amplification of the androgen receptor gene and progression of human prostate cancer. Nat Genet 1995;401–406.
  103. Palmberg C, Koivisto P, Hyytinen E, Isola J, Visakorpi T, Kallioniemi OP, Tammela T: Androgen receptor gene amplification in a recurrent prostate cancer after monotherapy with the nonsteroidal potent antiandrogen Casodex (bicalutamide) with a subsequent favorable response to maximal androgen blockade. Eur Urol 1997;31:216–219.
    External Resources
  104. Culig Z, Hobisch A, Cronauer MV, Radmayr C, Trapman J, Hittmair A, Bartsch G, Klocker H: Androgen receptor activation in prostatic tumor cell lines by insulin–like growth factor–I, keratinocyte growth factor and epidermal growth factor. Cancer Res 1994;54:5474– 5478.
  105. Klocker H, Culig Z, Eder IE, Nessler–Menardi C, Hobisch A, Putz T, Bartsch G, Peterziel H, Cato AC: Mechanism of androgen receptor activation and possible implications for chemoprevention trials. Eur Urol 1999;35: 413–419.
    External Resources
  106. Culig Z, Hobisch A, Cronauer M, Radmayr C, Hittmair A, Zhang J, Thurnher M, Bartsch G, Klocker H: Regulation of prostatic growth and function by peptide growth factors. Prostate 1996;28:329–405.
  107. Zhu X, Liu JP: Steroid–independent activation of androgen receptor in androgen–independent prostate cancer. A possible role for the MAP kinase signal transduction pathway. Mol Cell Endocr 1997;134:9–14.
    External Resources
  108. Culig Z, Hobisch A, Bartsch G, Klocker H, Peterziel H, Gast A, Cato ACB: Androgens, protein kinase A activators, and growth factors use different mechanisms to activate the androgen receptor. J Urol 1999;161:51.
    External Resources
  109. Yeh S, Lin HK, Kang HY, Thin TH, Lin MF, Chang C: From HER2/Neu signal cascade to androgen receptor and its coactivators: A novel pathway by induction of androgen target genes through MAP kinase in prostate cancer cells. Proc Natl Acad Sci USA 1999;96: 5458–5463.
  110. Peterziel H, Mink S, Schonert A, Becker M, Klocker H, Cato ACB: Rapid signalling by androgen receptor in prostate cancer cells. Oncogene 1999;18:6322–6329.
    External Resources
  111. Nazareth LV, Weigel NL: Activation of the human androgen receptor through a protein kinase A signaling pathway. J Biol Chem 1996;271:19900–19907.
    External Resources
  112. Sadar MD: Androgen–independent induction of prostate–specific antigen gene expression via cross–talk between the androgen receptor and protein kinase A signal transduction pathways. J Biol Chem 1999;274:7777–7783.
    External Resources
  113. Eder IE, Culig Z, Ramoner R, Thurnher M, Putz T, Nessler–Menardi C, Tiefenthaler M, Bartsch G, Klocker H: Inhibition of LNCaP prostate cancer cells by means of androgen receptor antisense oligonucleotides. Cancer Gene Ther 2000;7:997–1007.
    External Resources
  114. Geiger T, Muller M, Monia BP, Fabbro D: Antitumor activity of a c–raf antisense oligonucleotide in combination with standard chemotherapeutic agents against various human tumors transplanted subcutaneously into nude mice. Clin Cancer Res 1997;3:1179– 1185.
  115. Geiger T, Muller M, Dean NM, Fabbro D: Antitumor activity of a PKC–α antisense oligonucleotide in combination with standard chemotherapeutic agents against various human tumors transplanted into nude mice. Anticancer Drug Des 1998;13:35–45.
    External Resources
  116. Burfeind P, Chernicky CL, Rininsland F, Ilan J, Ilan J: Antisense RNA to the type I insulin–like growth factor receptor suppresses tumor growth and prevents invasion by rat prostate cancer cells in vivo. Proc Natl Acad Sci USA 1996;93:7263–7268.
    External Resources
  117. Putz T, Culig Z, Eder IE, Nessler–Menardi C, Bartsch G, Grunicke H, Überall F, Klocker H: Epidermal growth factor (EGF) receptor blockade inhibits the action of EGF, insulin–like growth factor I, and a protein kinase A activator on the mitogen–activated protein kinase pathway in prostate cancer cell lines. Cancer Res 1999;59:227–233.
    External Resources
  118. Ciardello F, Tortora G: Interactions between the epidermal growth factor receptor and type I protein kinase A: Biological significance and therapeutic implications. Clin Cancer Res 1998;4:821–828.
    External Resources
  119. Craft N, Shostak Y, Carey M, Sawyers CL: A mechanism for hormone–independent prostate cancer through modulation of androgen receptor signaling by the HER–2/neu tyrosine kinase. Nat Med 1999;5:280–285.
    External Resources
  120. Nesterova M, Noguchi K, Park YG, Lee YN, Cho–Chun YS: Compensatory stabilization of RIIbeta protein, cell cycle deregulation, and growth arrest in colon and prostate carcinoma cells by antisense–directed down–regulation of protein kinase A RIα protein. Clin Cancer Res 2000;6:3434–3441.
    External Resources
  121. Newmark JR, Hardy DO, Tonb DC, Carter BS, Epstein JI, Isaacs WB, Brown TR, Barrack ER: Androgen receptor gene mutations in human prostate cancer. Proc Natl Acad Sci USA 1992;89:6319–6323.
    External Resources
  122. Tan J, Sharief Y, Hamil KG, Gregory CW, Zang DY, Sar M, Gumerlock PH, deVere White RW, Pretlow TG, Harris SE, Wilson EM, Mohler JL, French FS: Dehydroepiandrosterone activates mutant androgen receptors expressed in the androgen–dependent human prostate cancer xenograft CWR22 and LNCaP cells. Mol Endocrinol 1997;11:450–459.
    External Resources

Article / Publication Details

First-Page Preview
Abstract of Review

Published online: October 29, 2001
Issue release date: September 2001

Number of Print Pages: 11
Number of Figures: 3
Number of Tables: 1

ISSN: 0302-2838 (Print)
eISSN: 1873-7560 (Online)

For additional information: https://www.karger.com/EUR

Copyright / Drug Dosage / Disclaimer

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

Article Tools
Article Details

2001, Vol.40, No. 3

September 2001

Article

Recommend This
TOP